Details of the Drug Formulations

General Information of Drug (ID: DMSB068)

Drug Name
PF-04449913 Drug Info
Synonyms
Glasdegib; 1095173-27-5; PF 04449913; UNII-K673DMO5H9; K673DMO5H9; CHEMBL2043437; Glasdegib (PF-04449913); Glasdegib [USAN:INN]; Glasdegib (USAN/INN); PF-04449913;Glasdegib; GTPL8201; Glasdegib(PF-04449913); EX-A858; MolPort-035-789-706; SFNSLLSYNZWZQG-VQIMIIECSA-N; ZINC68251434; PF-913; BDBM50385635; 2640AH; AKOS027324121; CS-2
Indication
Disease Entry ICD 11 Status REF
Chronic myelomonocytic leukaemia 2A40 Approved [1]
Solid tumour/cancer 2A00-2F9Z Approved [2]
Cross-matching ID
PubChem CID
25166913
ChEBI ID
CHEBI:145428
CAS Number
1095173-27-5
TTD ID
D0S5LO
INTEDE ID
DR0774
ACDINA ID
D01126

Full List of Drug Formulations Containing This Drug

Glasdegib 100 mg tablet
Company Formulation ID FDA Description
Pfizer Laboratories Div Pfizer F24309 Microcrystalline Cellulose; Dibasic Calcium Phosphate Anhydrous; Sodium Starch Glycolate; Magnesium Stearate; Hypromellose; Titanium Dioxide; Lactose Monohydrate; Macrogol; Triacetin; Iron Oxide Yellow; Iron Oxide Red
------------------------------------------------------------------------------------
Glasdegib 25 mg tablet
Company Formulation ID FDA Description
Pfizer Laboratories Div Pfizer F24372 Microcrystalline Cellulose; Dibasic Calcium Phosphate Anhydrous; Sodium Starch Glycolate; Magnesium Stearate; Hypromellose; Titanium Dioxide; Lactose Monohydrate; Macrogol; Triacetin; Iron Oxide Yellow; Iron Oxide Red
------------------------------------------------------------------------------------

References

1 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)